In­di­v­ior gets a speedy re­view for opi­oid ad­dic­tion drug as FDA vows to fight a cri­sis

With the FDA vow­ing to do every­thing in its pow­er to help fight the coun­try’s opi­oid ad­dic­tion cri­sis, reg­u­la­tors have hand­ed In­di­v­ior a pass on­to the in­side track at the agency, promis­ing a speedy re­view of its opi­oid ad­dic­tion ther­a­py.

The FDA’s pri­or­i­ty re­view process slash­es 4 months off the stan­dard 10-month ap­proach. That means In­di­v­ior {LON: IN­DV} will be up for a de­ci­sion by the end of No­vem­ber for RBP-6000, a once-month­ly slow-re­lease ver­sion of the opi­oid de­pen­dence drug buprenor­phine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER